V1RG12 inhibitors are a class of chemical compounds specifically developed to target and obstruct the activity of the V1RG12 protein. This protein is a part of the vacuolar-type H+-ATPase (V-ATPase) complex, which is integral to the process of proton transport across cellular membranes. V1RG12 is a component of the V1 domain of the V-ATPase, which plays a critical role in the hydrolysis of ATP, a reaction that powers the proton pumps responsible for maintaining the acidic environment within various intracellular compartments, such as endosomes, lysosomes, and the Golgi apparatus. By influencing the V1RG12 protein, these inhibitors can impact the overall function and efficiency of the V-ATPase complex.
The V1RG12 inhibitors exert their effects by binding to the V1RG12 protein, disrupting its interaction with other subunits of the V1 domain within the V-ATPase complex. This interference can impair the protein's ability to participate in ATP hydrolysis or stabilize the V1 domain assembly. Consequently, the proton pumping activity of the V-ATPase is affected, leading to alterations in the pH regulation and proton gradient across cellular compartments. The exploration of V1RG12 inhibitors provides valuable insights into the specific role of V1RG12 within the V-ATPase complex and helps to elucidate the broader implications of its inhibition on cellular processes related to proton transport and pH balance.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine inhibits the Hedgehog signaling pathway, which may lead to the downregulation of V1RG12 expression. | ||||||
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $76.00 $139.00 | 23 | |
Itraconazole can inhibit the Hedgehog pathway, potentially reducing the expression of V1RG12. | ||||||
GANT61 | 500579-04-4 | sc-202630 sc-202630A sc-202630B | 1 mg 5 mg 10 mg | $63.00 $128.00 $200.00 | 6 | |
GANT61 inhibits GLI-mediated transcription, a downstream target of the Hedgehog pathway, possibly decreasing V1RG12 expression. | ||||||
Glasdegib | 1095173-27-5 | sc-507353 | 5 mg | $165.00 | ||
Glasdegib targets the Hedgehog pathway, which could result in the inhibition of V1RG12 expression. | ||||||
Vismodegib | 879085-55-9 | sc-396759 sc-396759A | 10 mg 25 mg | $80.00 $96.00 | 1 | |
Vismodegib suppresses the Hedgehog signaling pathway, which may result in the inhibition of V1RG12 expression. | ||||||
SANT-1 | 304909-07-7 | sc-203253 | 5 mg | $132.00 | 5 | |
SANT-1 inhibits the Hedgehog pathway, potentially reducing the expression of V1RG12. | ||||||
IWP-2 | 686770-61-6 | sc-252928 sc-252928A | 5 mg 25 mg | $94.00 $286.00 | 27 | |
IWP-2 inhibits Wnt signaling, which may indirectly affect the expression of V1RG12. | ||||||
PARP Inhibitor XI, DR2313 | 284028-90-6 | sc-202756 | 5 mg | $63.00 | ||
XAV939 suppresses Wnt signaling, potentially leading to the downregulation of V1RG12 expression. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $210.00 $320.00 $1250.00 | 1 | |
LGK974 inhibits Wnt signaling, which may result in the inhibition of V1RG12 expression. | ||||||
PRI-724 | 1422253-38-0 | sc-507535 | 25 mg | $255.00 | ||
PRI-724 inhibits the interaction between β-catenin and CBP, potentially reducing the expression of V1RG12. | ||||||